semaglutide and ed Treatment — Zera Health Semaglutide: Double-edged Sword with Risks
Description
Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy
Semaglutide 1.0 mg reduced the risk of MACE and all cause death- 18% reduction in risk of MACE & 20% reduction in risk of all-cause death
FDA Disclosure These statements have not been evaluated by the Food and Drug Administration
In pancreatic beta cells, semaglutide stimulates glucose-dependent insulin secretion, meaning it promotes insulin release only when blood glucose levels are elevated
